Cargando…
Biologic treatment of Japanese patients with inflammatory bowel disease
BACKGROUND: There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. METHODS: An online survey was conducte...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211510/ https://www.ncbi.nlm.nih.gov/pubmed/30384833 http://dx.doi.org/10.1186/s12876-018-0892-x |
_version_ | 1783367349712191488 |
---|---|
author | Mahlich, Jörg Matsuoka, Katsuyoshi Sruamsiri, Rosarin |
author_facet | Mahlich, Jörg Matsuoka, Katsuyoshi Sruamsiri, Rosarin |
author_sort | Mahlich, Jörg |
collection | PubMed |
description | BACKGROUND: There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. METHODS: An online survey was conducted among Japanese patients with IBD (n = 1035). Socioeconomic as well as treatment related information was collected. Logistic regression was applied to analyze the determinants of biologic treatment. RESULTS: Younger age (≤ 40 years vs. > 65 years; OR:0.24), time since diagnosis (< 2 years vs. < 15 years; OR: 4.16), surgical history (OR:1.98) and visiting university hospitals (university hospitals vs. clinics; OR: 0.47) were associated with biologic treatment for Japanese IBD patients. CONCLUSIONS: Currently, biologics have been used in younger IBD patients which may give rise to the presence of an age bias in biologic treatment. Further studies are required to confirm these results and to define appropriate IBD patients who should be treated with biologic agent. |
format | Online Article Text |
id | pubmed-6211510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62115102018-11-08 Biologic treatment of Japanese patients with inflammatory bowel disease Mahlich, Jörg Matsuoka, Katsuyoshi Sruamsiri, Rosarin BMC Gastroenterol Research Article BACKGROUND: There is little information regarding the use of biologics in Inflammatory Bowel Disease (IBD) patients in Japan. The aim of this study was to determine the factors associated with the use of biologics in the treatment of Japanese patients with IBD. METHODS: An online survey was conducted among Japanese patients with IBD (n = 1035). Socioeconomic as well as treatment related information was collected. Logistic regression was applied to analyze the determinants of biologic treatment. RESULTS: Younger age (≤ 40 years vs. > 65 years; OR:0.24), time since diagnosis (< 2 years vs. < 15 years; OR: 4.16), surgical history (OR:1.98) and visiting university hospitals (university hospitals vs. clinics; OR: 0.47) were associated with biologic treatment for Japanese IBD patients. CONCLUSIONS: Currently, biologics have been used in younger IBD patients which may give rise to the presence of an age bias in biologic treatment. Further studies are required to confirm these results and to define appropriate IBD patients who should be treated with biologic agent. BioMed Central 2018-11-01 /pmc/articles/PMC6211510/ /pubmed/30384833 http://dx.doi.org/10.1186/s12876-018-0892-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Mahlich, Jörg Matsuoka, Katsuyoshi Sruamsiri, Rosarin Biologic treatment of Japanese patients with inflammatory bowel disease |
title | Biologic treatment of Japanese patients with inflammatory bowel disease |
title_full | Biologic treatment of Japanese patients with inflammatory bowel disease |
title_fullStr | Biologic treatment of Japanese patients with inflammatory bowel disease |
title_full_unstemmed | Biologic treatment of Japanese patients with inflammatory bowel disease |
title_short | Biologic treatment of Japanese patients with inflammatory bowel disease |
title_sort | biologic treatment of japanese patients with inflammatory bowel disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211510/ https://www.ncbi.nlm.nih.gov/pubmed/30384833 http://dx.doi.org/10.1186/s12876-018-0892-x |
work_keys_str_mv | AT mahlichjorg biologictreatmentofjapanesepatientswithinflammatoryboweldisease AT matsuokakatsuyoshi biologictreatmentofjapanesepatientswithinflammatoryboweldisease AT sruamsirirosarin biologictreatmentofjapanesepatientswithinflammatoryboweldisease |